Skip to content

Peptides, hormones and pipeline drugs

Glucagon receptor agonist

A glucagon receptor agonist activates the receptor for glucagon, a hormone that raises blood sugar but may also increase energy use and liver fat burning.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionA glucagon receptor agonist activates the receptor for glucagon, a hormone that raises blood sugar but may also increase energy use and liver fat burning.

What it means

Glucagon is made by the pancreas and usually works opposite insulin: it tells the liver to release sugar when levels fall. It also increases fat burning in the liver and may raise the calories the body uses.

On its own, extra glucagon would push blood sugar up. In weight-loss drugs it is paired with GLP-1 action, which lowers blood sugar and appetite, so the two effects balance. Examples include survodutide and mazdutide (glucagon plus GLP-1) and retatrutide (glucagon plus GLP-1 plus GIP).

Because glucagon acts strongly on the liver, these drugs are also being tested for fatty liver disease. Researchers are watching for effects on heart rate and other safety signals.

Do not confuse these with emergency glucagon kits, which treat severe low blood sugar.

Why it matters

Glucagon is the third hormone target that sets several pipeline drugs apart from today's approved medicines.

Related terms

SurvodutideMazdutideRetatrutideTriple agonist

Sources

  1. PubMed: glucagon receptor agonism in obesity

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error